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Available online 20 August 2018Background:Risk factors affecting earlymorality of patientswith Escherichia colibloodstream infection (BSI)were
investigated including the host-pathogen-treatment tripartite components.
Methods: Six general hospitals in South Korea participated in this multicentre prospective observational study
fromMay 2016 to April 2017 and a total of 1492 laboratory-conﬁrmed E. coli BSI cases were studied. Cox regres-
sion was used to estimate risks of the primary endpoint, i.e., all-cause mortality within 30 days from the initial
blood culture. Six multivariate analysis models were constructed in accordance to the clinical importance and
intra- and inter-component multicollinearity.
Findings: Among the 1492 E. coli BSI cases, 9.5% (n= 141) patients expired within 30 days. Six models of multi-
variate analysis indicated risk factors of critical illness, primary infection of peritoneum, and chronic liver disease
including cirrhosis for host variables; of phylogenetic group B2, ST131-sublineage H30Rx, multidrug resistance,
group 1 CTX-M extended-spectrum beta-lactamase production, and having either of fyuA, afa, and sfa/foc viru-
lence genes for causative E. coli pathogen variables; and of delayed deﬁnitive therapy for antimicrobial treatment
variables. In addition, as a protective factor, primary urinary tract infection was identiﬁed.
Interpretation:Despite decades' effort searching for the risk factors for E. coliBSI, systemicunderstanding covering
the entire tripartite component is still lacking. This studydetailed the organic impact of host-pathogen-treatment
tripartite components for early mortality in patients with E. coli BSI.Medicine
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Bloodstream infection (BSI) is a widely aware burden causing mor-
bidity and mortality in patients [1,2] and increasing medical costs [3].
To conﬁrm the BSI [4], polymerase chain reaction (PCR) [5] and
Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spec-
trometer (MALDI-TOF/MS) [6] have been proposed for rapid diagnosis
however, blood culture is still a gold standard to verify foreign micro-
organic invaders in bloodstream. An antimicrobial susceptibility testing, Research Institute of
onju-ro, Seoul 06273,
an open access article under(AST) successive to the blood culture is indeed critical to decide a regi-
men active in vitro for deﬁnitive treatment.
Escherichia coli is among human intestinalmicroﬂorawhich is usual-
ly harmless and even has amutual beneﬁt through its gut habitat. How-
ever, certain serotype causes intestinal infections and extra-intestinal
pathogenic E. coli (ExPEC) leads opportunistic infections including uri-
nary tract infection (UTI) and BSI [7]. E. coli is a leading BSI-causative
pathogen [8,9], and beta-lactams, ﬂuoroqinolones, and sulfonamides
are often used to treat the infections. A predominant ExPEC clone se-
quence type (ST) 131 [10] is commonly resistant to multiple drugs
[10]. Of particular, the ﬂuoroquinolone-resistant sublineages H30R
and H30Rx frequently harbour the gene for CTX-M-type extended-
spectrum beta-lactamases (ESBLs) leading to inappropriate therapy
[10].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
E. colibloodstream infection (BSI) an interesting research topic not
only for the clinicians but also for the clinical microbiologists. Con-
sequently, much research has been carried out in both fields and a
lot informationwas available out of the reports. Since urinary tract
is another habitual target for extra-intestinal pathogenic E. coli,
the associated host factors were frequently assessed, such as in-
fection of hospital/community origin, sex and age, as well as
uropathogenic factors possessed by E. coli, and resistance to
beta-lactams, fluoroquinolones and sulfonamides useful for both
infections of bloodstream and urinary tract. The massive knowl-
edge for the E. coli BSI was much enriched, and we now know
that which circumstance is critical for the prognosis of the infec-
tious disease. However, any complicated situation, for instance,
increased rate of drug resistance and dissemination of a specific
bacterial clones, prohibited any further prediction for the progno-
sis. This could be derived from the simple model estimating the
outcomes of E. coli BSI using only the host factors.
Added value of this study
For the prospective observational study, we collected the entire
E. coli blood isolates, together with clinical data, and antimicrobial
treatment information from every E. coli BSI incidence. This study
design allowed us a multidisciplinary analysis for the disease. In
addition, owing to a fine layout of multivariate analysis, underesti-
mation of any variables was reduced to minimum. Especially, the
strong clonality of pathogen factors frequently eliminated the haz-
ardous value and the antimicrobial resistance had strong correla-
tion with treatment factors. We fractionized the pathogen-, and
treatment-associated factors into six and the hazardous value of
the factors were able to be ruled in. Finally, worrisome pathogen
clones were identified, and antimicrobial resistance, not only for
the number of resistant drugs but also for the resistance determi-
nants, were listed as risk factors together with three virulence
genes associated with siderophore, adhesion and invasion. In ad-
dition, the importance of prompt definitive therapy was
highlighted.
Implications of all the available evidence
Collecting the clinical data, identification of the pathogen traits
and proper application of antimicrobial treatment seems to be crit-
ical for the E. coli BSI. Fine prognostic estimation system could be
schemed out for better estimating the outcomes of the prevailing
infectious disease.
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BSI. Male patients, infection of hospital origin (HO) [11], Charlson co-
morbidity index [12], and Sequential Organ Failure Assessment
(SOFA) score are noted host-associated hazardous factors for earlymor-
tality. In addition, resistance to ﬂuoroquinolones and to 3rd-generation
cephalosporins [13,14], ESBL production [15], and possessing
siderophore genes such as fyuA [16], and ireA [17] are the pathogen-
associated risk factors. The drug resistance is a decisive treatment-
associated risk factor [11]. However, puzzling out those risk factors for
the organic impact of host-pathogen-treatment tripartite components
to the disease prognosis is difﬁcult. The studies are often designed lack-
ing one of the three components and themulticollinearity between var-
iables are simply kicked out in favor of the clinically important variablesfor the main analysis. Hence, a multicentre prospective observational
study without the conceptual difﬁculties was assessed for whole-year
incidence of E. coli BSI to better understand the tripartite components
associated with early mortality.
2. Methods
2.1. Study design
The study was conducted as a prospective observational study for
entire episodes of E. coli BSI occurred between May 2016 and April
2017 in six general hospitals of 715 to 1050 beds (mean, 849.5 beds)
participating in a national surveillance system in South Korea compati-
ble to the Global Antimicrobial Surveillance System (GLASS), namely
Kor-GLASS (Fig. 1) [18]. All the local ethical committee approval at
each participating hospital was expedited or waived owing to the pure-
ly observational nature of the study. Cases were detected through the
daily review of blood culture results. Among a total of 67,803 patients
subjected for blood culture, E. coli isolateswere recovered from1510pa-
tients (Fig. 1) and, following the elimination of 18 episodes of expira-
tions at day 0, 1492 cases were included in the analysis. Of note, 19
follow-up-loss cases either by transfer (n = 12) or by discharge (n=
7) within 2 days of initial blood culture were excluded for the analysis
of antimicrobial treatment. For the sequential isolation of duplicate
E. coli from one patient, ﬁrst isolate was taken for analysis and the fol-
lowings were discarded. One investigator of each hospital reviewed
the patients' medical records for demographic characteristics,
infection-related clinical data, morbidities and underlying illness.
Charlson comorbidity index [19], and SOFA [20] score were calculated
at the analyzing centre for the day of initial blood culture. Prognoses
were followed-up until hospital discharge or at least for 30 days. All
data were recorded on a pre-formatted spreadsheet and submitted via
an email to the analyzing centre without monitoring. All blood isolates
were transferred to the analyzing centre and themicrobiological assess-
ment was carried out in the laboratory. Performing the microbiological
assessment was blinded to patient information.
2.2. Deﬁnitions
A laboratory-conﬁrmed E. coli BSI was deﬁned as positive E. coli cul-
ture identiﬁed from one or more blood specimens [4]. HO infection was
speciﬁed as the case that a patient admitted for ≥2 calendar days at hos-
pitals including the previous health care facility before transfer at the
day of initial blood culture. Early mortality was deﬁned as all-cause
mortality within 30 days from the initial blood culture. Critically ill pa-
tients were deﬁned as those with SOFA score at ≥9. Non-susceptibility
(NS) to a drug class was deﬁned as NS in vitro to at least one drug in a
class and the resistance phenotypes were classiﬁed as drug susceptible
(DS, susceptible to all drugs tested), drug resistant (DR, NS to one or
two drug classes) and multidrug resistance (MDR, NS to more than
three drug classes but two) following Magiorakos et al. [21] with few
modiﬁcations. Empirical antimicrobial therapy was deﬁned as an initial
therapy without any AST results of the causative pathogen, and deﬁni-
tive antimicrobial therapy as administration of revised antimicrobial
regimen based on the AST results. Delayed deﬁnitive therapy was if re-
vised antimicrobial regimen was administered after 72 h. Adequate an-
timicrobial therapy was if the treatment regimen included at least one
antimicrobial drug active in vitro and both the dosage and route of ad-
ministration were in conformity with current medical standards.
2.3. Microbiological assessment
Bacterial species of the collected isolates were identiﬁed by MALDI-
TOF/MS using Bruker Biotyper™ system (Billerica, MA, USA). Strain typ-
ing was conducted by multilocus sequence typing (MLST) [22], and by
Fig. 1. Flowchart for the case selection of E. coli bloodstream infection for analysis. Number of E. coli blood isolates and the bed size are indicated by hospital with a line-association of the
district served by either in gray or in black. BSI, bloodstream infection.
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E. coli isolates, sublineagewas assessed [24]. Antimicrobial susceptibility
was tested by a disk diffusionmethod [25] for 18 drugs belonging to 12
drug classes, and the beta-lactamase genes were identiﬁed by PCR and
direct sequencing using gene-speciﬁc primers (Appendix Table S1)
[26]. Twenty-three virulence-associated genes associated with 12 viru-
lence characteristics were searched for by PCR. Details of the microbio-
logical assessment is available in the Appendix.2.4. Statistical analysis
All statistical analyses were performed in SPSS statistics (version 23,
IBM Corp., Armonk, NY, USA). Data were expressed as mean ± SD or
number (%) as appropriate. Categorical variables were compared by
Pearson's chi-square test or Fisher's exact test and continuous variables
were compared by independent two sample t-test. Associations be-
tween early mortality and risk factors were evaluated by using univari-
ate and multivariate Cox proportional hazard regression model. For
multivariate analysis, variables having P value b0·1 on the univariate
analysis were considered. To avoid multicollinearity, six multivariate
Cox models were constructed. All tests of signiﬁcance were two-
tailed; P values b0·05 were considered to be signiﬁcant. Proportional-
hazards assumption was evaluated by including an interaction term of
covariate*log-transformed time and by log-minus-log survival plots
(Appendix Fig. S1). Six models for Cox proportional multivariate analy-
sis were constructed considering both clinical importance and
multicollinearity between variables evaluated by chi-square test and t-
test (Appendix Fig. S2): model 1 including variables selected by step-
wise selection method; model 2 to model 5 including ﬁxed host vari-
ables and adaptable pathogen variables mandatorily one strain type
and one other genotype devoid of multicollinearity; and model 6 in-
cluding ﬁxed host variables and adaptable pathogen variables andman-
datorily a treatment variable devoid of multicollinearity (Appendix
Figure).2.5. Role of the funding source
The funder of the study had no role in the study design, data
collection, data analysis, interpretation, and writing of the report.
The corresponding author had full access to all the data in the
study and had ﬁnal responsibility for the decision to submit for
publication.3. Results
3.1. Characteristics of enrolled patients
From six general hospitals, 1492 laboratory-conﬁrmed E. coli BSI
cases were enrolled: mean 248·7 ± 91·5 cases/hospital, ranged from
122 to 365 by hospital (Fig. 1). Among the patients with E. coli BSI,
39·7% (n = 592) were male and their age was mean 69·0 ± 15·6
years resulting in 69·7% (n = 1040) being ≥65 years old (Table 1). Of
total, 19·4% (290/1492) cases were HO infection, 58·4% (n = 871)
were inpatients and 18·4% of those (161/871) stayed in intensive care
units (ICUs). SOFA scoring had a mean value of 3·6 ± 3·0 and 7·6%
(n = 114) patients were critically ill (SOFA [9]. Charlson comorbidity
index was mean 3·3 ± 1·8. Diabetes mellitus was the most observed
underlying disease (15·4%, 231/1492), of which 15 with complications,
and solid tumor (12·5%, n= 187) was followed. Around half (49.5%, n
= 738) of the BSI cases were secondary infection conﬁrmed by culture
and the most identiﬁed primary site of infection was urinary tract
(90.9%, 671/738).
3.2. Characteristics of E. coli blood isolates
3.2.1. Strain type
E. coli blood isolates were characterized as described in the Appen-
dix. More than half of the isolates belonged to the phylogenetic group
B2 (55·8%, 833/1492) and the remaining was composed with either
the group D (24·7%, n= 368) or A (19·4%, n= 289) (Table 2) with ex-
ceptional two isolates (0·1%) of the group B1. Among the identiﬁed 338
STs including 212 known-STs and 126 not-yet-numbered STs, ST131
was prevalent (24·1%, 359/1492) followed by ST95 (9·6%, n = 143),
ST69 (8·6%, n = 128), ST1193 (6·4%, n = 96), ST73 (4·6%, n = 69),
and ST38 (3·8%, n = 56). The ST131-sublineages were comprised
with non-H30 (5·3%, 19/359), H30 (11·1%, 40/359), H30R (33·7%,
121/359), and H30Rx (49·9%, 179/359).
3.2.2. Antimicrobial resistance
More than half of the E. coli blood isolates were MDR (58·0%, 865/
1492) and the rest was either DR (19·9%, n = 297) or DS (22·1%, n
= 330) (Table 2, Appendix). Of total, 31·0% (463/1492) E. coli blood iso-
lates harboured the blaCTX-M gene: 54·9% (254/463) were group 1
blaCTX-M gene and 48·9% (225/460) were group 9 blaCTX-M. Sixteen iso-
lates including 13 ST131-sublineage H30Rx, one ST38, one ST196, and
one ST1456 co-carried both genes for groups 1 and 9. Less frequently,
2·5% (34/1492) isolates harboured genes for plasmid-mediated AmpC,
Table 1
Patient-associated factors related to early mortality in patients with E. coli BSI.
Characteristics Totala Survival Early deathb Pc
(n = 1492) 1351 (90·5%) 141 (9·5%)
Demographic information
Sex (male) 592 (39.7%) 520 (38.5%) 72 (51.1%) 0.005
Age (in years, mean ± SD) 69·1 ± 15·7 69·0 ± 15·6 70·4 ± 15·8 0·287
Hospital origin 293 (19.6%) 241 (17.8%) 52 (36.9%) b0.001*
Comorbid condition
Inpatients 871 (58.4%) 773 (57.2%) 98 (69.5%) 0.005
ICU inpatients 161 (10.8%) 116 (8.6%) 45 (31.9%) b0.001*
Polymicrobial infection 86 (5.8%) 73 (5.4%) 13 (9.2%) 0.084
SOFA score (mean ± SD) 3·6 ± 3·0 3·2 ± 2·8 7·1 ± 3·2 b0·001*
Underlying diseased
Charlson comorbidity index (mean ± SD) 3·3 ± 1·8 3·3 ± 1·8 3·6 ± 1·8 0·095
Cerebrovascular diseases 36 (2.4%) 34 (2.5%) 2 (1.4%) 0.571
Peripheral vascular diseases 29 (1.9%) 29 (2.1%) 0 (0%) 0.104
Myocardial infarction 39 (2.6%) 37 (2.7%) 2 (1.4%) 0.576
Congestive cardiac insufﬁciency 6 (0.4%) 6 (0.4%) 0 (0%) N0.999
Hemiplegia 2 (0.1%) 2 (0.1%) 0 (0%) N0.999
Solid tumor 187 (12.5%) 164 (12.1%) 23 (16.3%) 0.180
Lymphoma 5 (0.3%) 4 (0.3%) 1 (0.7%) 0.392
Leukemia 11 (0.7%) 9 (0.7%) 2 (1.4%) 0.279
Diabetes mellitus 231 (14·6%) 210 (15.5%) 21 (14.9%) 0·900
Moderate or severe kidney diseases 88 (5.9%) 74 (5.5%) 14 (9.9%) 0.039
Chronic liver diseases including cirrhosis 49 (3.3%) 40 (3%) 9 (6.4%) 0.043
Chronic pulmonary diseases 17 (1.1%) 16 (1.2%) 1 (0.7%) N0.999
Dementia 22 (1.5%) 20 (1.5%) 2 (1.4%) N0.999
Ulcer 11 (0.7%) 10 (0.7%) 1 (0.7%) N0.999
Primary site of infectionc
Blood 33 (2.2%) 32 (2.4%) 1 (0.7%) 0.360
Urinary tract 671 (45.0%) 627 (46.4%) 44 (31.2%) 0.001
Biliary tract 26 (1.7%) 25 (1.9%) 1 (0.7%) 0.504
Respiratory tract 15 (1.0%) 9 (0.7%) 6 (4.3%) 0.002
Peritoneum 12 (0.8%) 7 (0.5%) 5 (3.5%) 0.003
Wound 11 (0.7%) 9 (0.7%) 2 (1.4%) 0.279
Otherse 3 (0.2%) 3 (0.2%) 0 (0%) N0.999
Unknown 744 (49.9%) 659 (48.8%) 85 (60.3%) 0.010
Laboratory data (mean ± SD)f
WBC (103/μL) 12·5 ± 10·9 12·3 ± 8·9 14·2 ± 22 0·038
Hemoglobin (g/dL) 11·4 ± 4·9 11·5 ± 5·1 10·1 ± 2·3 0·001
Platelet (109/L) 172·2 ± 94·2 177·2 ± 93·2 126·0 ± 91·8 0·001
Total bilirubin (mg/dL) 2·0 ± 3·6 1·8 ± 3·4 3·2 ± 5·0 b0·001*
Creatinine clearance (mg/dL) 1·5 ± 3·1 1·5 ± 3·2 1·9 ± 2·1 0·164
Prothrombin time (seconds) 14·5 ± 5·9 14·2 ± 5·6 18·6 ± 7·1 0·225
SD, standard deviation; WBC, white blood cells.
a The percentage was calculated out of total number of E. coli BSI cases.
b All-cause mortality within 30 days from the initial blood culture.
c P value is either from Pearson's chi-square test for categorical data or from t-test for continuous data. Bonferroni corrected signiﬁcance level was considered as P b 0.001 and the
signiﬁcant P values are indicated with asterisks.
d Underlying disease and primary site of infection could be multiple by patient.
e Cervix (n= 2) and eye (n= 1) were included.
f Five of total bilirubin data, two of creatinine clearance data, and ten of prothrombin time data were absent.
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late carried the blaKPC-2 gene.
3.2.3. Virulence determinants
Among the 23 virulence genes tested, mean 3·3± 2·4 were identi-
ﬁed per isolate (Table 2). The most identiﬁed gene was traT (58·3%, n
= 870), and usp (45·6%, n = 681), followed by fyuA (28·2%, n =
421), sat (22·3%, n = 332), vat (20·0%, n = 298), ETTT (19·8%, n =
295), ompT (17·6%, n= 263) and colibactin (16·1%, n = 240).
3.2.4. Clonal traits
Clonal traits of top six predominant STs, ST131, ST95, ST69, ST1193,
ST73, and ST38, covering 57·3% (n = 844) isolates were presented in
Fig. 2. The six clones largely belonged either to the phylogenetic group
B2 (ST131, ST95, ST1193, and ST73) or D (ST69, and ST38).The ST131 was frequently associated with HO (29·2%, 205/359), es-
pecially the sublineages H30R (28·9%, 35/121), and H30Rx (34·6%, 62/
179) were. Proportion of MDR showed gradual increase by sublineages
as 73·7% (14/19) non—H30, 75·0% (30/40) H30, 95·0% (115/121)
H30R, and 98·3% (176/179) H30Rx. Most of the ST131 carried the
group 1 (49·0%, 179/359) and/or the group 9 blaCTX-M genes (31·2%,
112/359): 66·9% (82/121) H30R with the group 9, and 92·2% (165/
179) H30Rxwith the group 1 blaCTX-M genes. Besides, relatively a great-
er proportion of H30 (12·5%, 5/40) harboured the blaAmpC genes. The
ST131 carried the hlyA (14·8%, 53/359), sat (46·2%, n = 166), fyuA
(33·1%, n = 119), cnf1 (22·6%, n = 81), traT (75·2%, n = 270), afa
(9·7%, n = 35), and usp (78·6%, n = 282) virulence genes more fre-
quently than other STs.
The secondmost ST95 was associated exceedingly with primary UTI
(73·6%, 103/140) andmajority of the clonewasDS (53·6%, n= 75). For
the third most ST69, a half of the isolates were linked with primary UTI
Table 2
Pathogen-associated factors related to early mortality in patients with E. col BSI.
Characteristics Totala Survival Early deathb Pc
(n = 1492) 1351 (90·5%) 141 (9·5%)
Strain type
Phylogenetic group A 289 (19·4%) 275 (20·4%) 14 (9·9%) 0·002
B2 833 (55·8%) 741 (54·8%) 92 (65·2%) 0·020
D 368 (24·7%) 333 (24·6%) 35 (24·8%) 0·999
ST131 359 (24·1%) 310 (22·9%) 49 (34·8%) 0·003
Non-H30 19 (1·3%) 17 (1·3%) 2 (1·4%) 0·699
H30 40 (2·7%) 34 (2·5%) 6 (4·3%) 0·264
H30R 121 (8·1%) 108 (8·0%) 13 (9·2%) 0·626
H30Rx 179 (12·0%) 151 (11·2%) 28 (19·9%) 0·004
ST95 143 (9·6%) 135 (10%) 8 (5·7%) 0·131
ST69 128 (8·6%) 117 (8·7%) 11 (7·8%) 0·874
ST1193 96 (6·4%) 83 (6·1%) 13 (9·2%) 0·151
ST73 69 (4·6%) 63 (4·7%) 6 (4·3%) N0·999
ST38 56 (3·8%) 53 (3·9%) 3 (2·1%) 0·359
Antimicrobial resistance categoryd
DS 330 (22·1%) 306 (22·6%) 24 (17·0%) 0·136
DR 297 (19·9%) 277 (20·5%) 20 (14·2%) 0·077
MDR 865 (58·0%) 768 (56·8%) 97 (68·8%) 0·007
Non-susceptible toe
Penicillins 1024 (68·6%) 918 (67·9%) 106 (75·2%) 0·086
Penicillins/beta-lactamase inhibitors 546 (36·6%) 476 (35·2%) 70 (49·6%) 0·001
1st-generation cephalosporins 987 (66·2%) 885 (65·5%) 102 (72·3%) 0·112
3rd/4th-generation cephalosporins 524 (35·1%) 457 (33·8%) 67 (47·5%) 0·002
Monobactams 402 (26·9%) 349 (25·8%) 53 (37·6%) 0·004
Cephamycins 77 (5·2%) 69 (5·1%) 8 (5·7%) 0·692
Carbapenems 3 (0·2%) 3 (0·2%) 0 (0%) 0·999
Aminoglycosides 463 (31·0%) 409 (30·3%) 54 (38·3%) 0·056
Fluoroquinolones 590 (39·5%) 521 (38·6%) 69 (48·9%) 0·019
Sulfonamides 494 (33·1%) 445 (32·9%) 49 (34·8%) 0·707
Glycylcyclines 3 (0·2%) 3 (0·2%) 0 (0%) N0·999
Polymyxins 3 (0·2%) 3 (0·2%) 0 (0%) N0·999
Resistance determinant
CTX-M ESBL 463 (31·0%) 403 (29·8%) 60 (42·6%) 0·003
Group 1 254 (17·0%) 216 (16·0%) 38 (27·0%) 0·002
Group 9 225 (15·1%) 202 (15·0%) 23 (16·3%) 0·710
Plasmid-mediated AmpC 37 (2·5%) 32 (2·4%) 5 (3·5%) 0·388
Carbapenemase 1 (0·1%) 0 (0%) 1 (0·7%) 0·095
Virulence determinants
No· of virulence determinantsf (mean ± SD) 3·3 ± 2·4 3·3 ± 2·4 3·9 ± 2·5 0·004
Haemolysis
hlyA, haemolysin A 107 (7·2%) 92 (6·8%) 15 (1·1%) 0·120
hlyE, avian E. coli haemolysin 52 (3·5%) 45 (3·3%) 7 (5·0%) 0·329
Toxins
sat, serine protease autotransporter 332 (22·3%) 293 (21·7%) 39 (27·7%) 0·111
vat, vacuolating autotransporter 298 (20·0%) 261 (19·3%) 37 (26·2%) 0·059
astA, heat-stable enterotoxin 34 (2·3%) 29 (2·1%) 5 (3·5%) 0·245
Siderophore
ireA, siderophore receptor 193 (12·9%) 176 (13·0%) 17 (12·1%) 0·895
iro, siderophore esterase 184 (12·3%) 165 (12·2%) 19 (13·5%) 0·686
fyuA, yersiniabactin 421 (28·2%) 366 (27·1%) 55 (39·0%) 0·004
iutA, ion uptake system 120 (8·0%) 105 (7·8%) 15 (10·6%) 0·253
Cytotoxicity
ETTT, type III secretion system 295 (19·8%) 268 (19·8%) 27 (19·1%) 0·912
Colibactin, genotoxic metabolite 240 (16·1%) 215 (15·9%) 25 (17·7%) 0·549
cnf1, cytotoxic necrotizing factor 173 (11·6%) 151 (11·2%) 22 (15·6%) 0·128
Bacteriocin
cvaC, colicin V 82 (5·5%) 78 (5·8%) 4 (2·8%) 0·175
Serum resistance
traT, outer membrane protein 870 (58·3%) 790 (58·5%) 80 (56·7%) 0·720
Invasion
afa, invasion protein 80 (5·4%) 66 (4·9%) 14 (9·9%) 0·017
ibeA, brain microvascular endothelial cell invasion 68 (4·6%) 61 (4·5%) 7 (5·0%) 0·831
ompT, outermembrane protease T 263 (17·6%) 238 (17·6%) 25 (17·7%) N0·999
Encapsulation
kpsMII, capsule synthesis 142 (9·5%) 123 (9·1%) 19 (13·5%) 0·097
Adhesion
papA, P ﬁmbriae 28 (1·9%) 25 (1·9%) 3 (2·1%) 0·743
sfa/foc, S ﬁmbriae minor subunit 108 (7·2%) 92 (6·8%) 16 (11·3%) 0·059
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Table 2 (continued)
Characteristics Totala Survival Early deathb Pc
(n = 1492) 1351 (90·5%) 141 (9·5%)
Others
usp, uropathogenic protein 681 (45·6%) 601 (44·5%) 80 (56·7%) 0·006
PAI, pathogenic island marker 83 (5·6%) 74 (5·5%) 9 (6·4%) 0·698
pic, protease involved in intestinal colonization 103 (6·9%) 96 (7·1%) 7 (5·0%) 0·483
SD, standard deviation.
a The percentage was calculated out of total number of E. coli blood isolates.
b All-cause mortality within 30 days from the initial blood culture.
c P value is either from Pearson's chi-square test for categorical data or from t-test for continuous data. Bonferroni corrected signiﬁcance level was considered as P b 0.0009 and no
variable was statistically signiﬁcant.
d Isolates categorized as XDR and PDRwere not identiﬁed. DS, drug susceptible; DR, drug resistant; MDR, multi-drug resistant; XDR, extensively drug resistant; PDR, pan-drug resistant
[21].
e Ampicillin and piperacillin for penicillins; amoxicillin-sulbactam for penicillins/beta-lactamase inhibitors; cephazolin for 1st-generation cephalosporins; cefotaxime, ceftazidime, and
cefepime for 3rd/4th-generation cephalosporins; cefoxitin for cephamycins; aztreonam for monobactam; imipenem, meropenem, and ertapenem for carbapenems; gentamicin and
amikacin for aminoglycosides; ciproﬂoxacin for ﬂuoroquinolone; trimethoprim-sulfamethoxazole for sulfonamides; tigecycline for glycylcyclines; colistin for polymyxins.
f Number of identiﬁed virulence determinants among the 23 genes tested.
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and the ST73 possessed much more genes for virulence (mean, 7·1 ±
3·7) compared to the other STs. Finally, ST38 frequently carried the
group 9 blaCTX-M gene (40·7%, 22/54).
3.3. Characteristics of antimicrobial regimen
3.3.1. Antimicrobial regimen for empirical therapy
Among the 1473 antimicrobial treatment follow-up cases, 1443 pa-
tients (98·0%) received empirical antimicrobial therapy for Gram-
negative bacteria and 1142 of those were adequate (Table 3). The
other 30 patients took either not-for-Gram-negative antimicrobial ther-
apies (n= 29) or noneby refusal (n= 1).More than half of the patients
were treated with 3rd/4th-generation cephalosporins (55·6%, n =
819), and 20·0% (n= 295) with ﬂuoroquinolones, followed by carba-
penems (14·0%, n = 206), penicillins/beta-lactamase inhibitors
(12·9%, n = 190), penicillins (2·4%, n= 35) and 1st-generation cepha-
losporins (1·0%, n = 14). The rate of adequacy for antimicrobial treat-
ment was greater in combination therapy (90·2%, 138/153) than in
monotherapy (81·2%, 1042/1284). Exceptionally, choice ofFig. 2.Genotypic andphenotypic diversity of E. coli blood isolates by sixmost strain types. Thepr
0.05) determined by Pearson's chi-square test is in bold. A smaller proportion compared to that
in red-gradients. ST, sequence type; DS, drug-susceptible; DR, drug-resistant; MDR, multidrugcarbapenems, which all but three E. coli isolates were susceptible to,
was always adequate for treatment whether they used alone or in
combination.
Increased preference of both carbapenems monotherapy (22·5%,
25/111), and penicillins/beta-lactamase inhibitors monotherapy
(17·1%, n = 19) were notable for the critically ill patients. On the con-
trary, ﬂuoroquinolones monotherapy (1·8%, n = 2), and 3rd/4th-
generation cephalosporines monotherapy (34·2%, n = 38) were less
preferred options targeting on those patients than those for total. For
ICU inpatients (n = 161), both ﬂuoroquinolones monotherapy (4·3%,
n= 7), and 3rd/4th-generation cephalosporines monotherapy (42·2%,
n = 68) were also less favored. Preference of 3rd/4th-generation
cephalosporines was dropped from 55.6% (819/1473) of total to 40·0%
(116/290) targeting HO infection.
3.3.2. Antimicrobial regimen for deﬁnitive therapy
Among 331 patients taking inadequate empirical therapy, 56·8% (n
= 188) were treated with deﬁnitive antimicrobial therapy within 72 h.
Carbapenems (70·7%, monotherapy:combination therapy = 130:3)
were a leading choice for the revision and the followings were 3rd/oportion of isolates having the geno/phenotype is indicated and statistical signiﬁcance (P b
of total is indicated in blue-gradients and a greater proportion than that of total is indicated
resistance; ESBL, extended-spectrum beta-lactamase.
Table 3
Empirical antimicrobial therapy for the characteristic patients with E. coli BSIa.
Antimicrobial choice for empirical therapy Total Early mortality Adequate treatment Critically illb ICU inpatients HO infection
n= 1473 n = 141 Pc n= 1142 Pc n= 111 Pc n = 161 Pc n= 290 Pc
Penicillins Monotherapy 31 (2·1%) 4 (2.8%) 0·531 8 (0.7%) b0·001* 5 (4.5%) 0·078 14 (8.7%) b0·001* 14 (4.8%) b0·001*
Combination therapy 4 (0·3%) 1 (0.7%) 0·332 3 (0.3%) 1·000 0 (0%) 1·000 4 (2.5%) b0·001* 1 (0.3%) 0·584
Penicillins/beta-lactamase inhibitors Monotherapy 161 (10·9%) 22 (15.6%) 0·066 147 (12.9%) b0·001* 19 (17.1%) 0·039 25 (15.5%) 0·060 5 (1.7%) 0·528
Combination therapy 29 (2·0%) 7 (5·0%) 0·016 27 (2.4%) 0·043 6 (5.4%) 0·018 4 (2.5%) 0·549 9 (3.1%) 0·153
1st-generation cephalosporins Monotherapy 7 (0·5%) 0 (0%) 1·000 6 (0.5%) 1·000 0 (0%) 1·000 1 (0.6%) 0·556 4 (1.4%) 0·031
Combination therapy 7 (0·5%) 1 (0.7%) 0·506 7 (0.6%) 0·360 1 (0.9%) 0·423 0 (0%) 1·000 2 (0.7%) 0·630
3rd/4th-generation cephalosporins Monotherapy 747 (50·7%) 49 (34.8%) b0·001* 572 (50.1%) 0·383 38 (34.2%) b0·001* 68 (42.2%) 0·024 116 (40·0%) b0·001*
Combination therapy 72 (4·9%) 9 (6.4%) 0·408 60 (5.3%) 0·250 11 (9.9%) 0·019 6 (3.7%) 0·565 20 (6.9%) 0·093
Carbapenems Monotherapy 165 (11·2%) 25 (17.7%) 0·016 165 (14.4%) b0·001* 25 (22.5%) b0·001* 22 (13.7%) 0·290 39 (13.4%) 0·178
Combination therapy 41 (2·8%) 10 (7.1%) 0·004 41 (3.6%) b0·001* 2 (1.8%) 0·764 3 (1.9%) 0·614 8 (2.8%) N0·999
Fluoroquinolones Monotherapy 165 (11·2%) 4 (2.8%) b0·001* 98 (8.6%) b0·001* 2 (1.8%) b0·001* 7 (4.3%) b0·001* 26 (9.0%) 0·212
Combination therapyd 130 (8·8%) 25 (17.7%) b0·001* 122 (10.7%) b0·001* 15 (13.5%) 0·081 11 (6.8%) 0·461 30 (10.3%) 0·300
Otherse 8 (0·5%) 5 (3.5%) b0·001* 5 (0.4%) 0·389 1 (0.9%) 0·467 3 (1.9%) 0·047 7 (2.4%) b0·001*
Not-for-Gram-negatives 29 (2·0%) 2 (1.4%) – 0 (0%) – 1 (0.9%) – 3 (1.9%) – 8 (2.8%) –
Refusal of antimicrobial therapy 1 (0·1%) 0 (0%) – 0 (0%) – 0 (0%) – 1 (0.6%) – 0 (0%) –
ICU, intensive care unit; HO, hospital-origin.
a Nineteen cases of the follow-up-loss before 2nd day of the treatment were excluded from the analysis. The percentage was calculated out of total number of E. coli BSI cases.
b Critically ill patients were deﬁned as those with SOFA score at ≥9.
c P value is from Pearson's chi-square test. Bonferroni corrected signiﬁcance level was considered as P b 0.003 and the signiﬁcant P values are indicated with asterisks.
d Combination ﬂuoroqniolone therapy was always with beta-lactams.
e Glycylcyclines (n= 4), rifampicin (n= 2), cephamycins (n= 1), and sulfonamides (n= 1) were included.
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Table 4
Uni- and multivariate analysis by Cox-regression model for early mortality in patients with E. col BSIa.
Variables for Univariate analysis Multivariate model 1 Multivariate model 2 Multivariate model 3
HR [95% CI] P HR [95% CI] P VIF HR [95% CI] P VIF HR [95% CI] P
Host
Critically ill 6·78 [4·75–9·69] b0·001 5·85
[4·06–8·42]
b0·001* 1·01 5·76
[3·98–8·35]
b0·001* 1·02 5·67
[3·92–8·21]
b0·001*
Polymicrobial infection 1·72 [0·97–3·05] 0·061 1·63
[0·91–2·89]
0·098 1·01 1·57
[0·87–2·84]
0·137 1·01 1·58
[0·87–2·85]
0·130
Primary infection of peritoneum 4·82 [1·98–11·78] b0·001 2·80
[1·10–7·15]
0·031 1·01 2·85
[1·13–7·18]
0·026 1·01 3·04
[1·21–7·69]
0·018
Primary infection of urinary tract 0·54 [0·38–0·77] b0·001 0·56
[0·39–0·81]
b0·001* 1·03 0·55
[0·38–0·79]
0·001* 1·07 0·55
[0·38–0·79]
b0·001*
Moderate to severe kidney disease 1·81 [1·04–3·14] 0·037 1·24
[0·69–2·22]
0·465 1·02 1·18
[0·66–2·12]
0·582
Chronic liver disease incl. Cirrhosis 1·80 [1·04–3·13] 0·027 2·09
[1·06–4·12]
0·033 1·00 2·11
[1·06–4·20]
0·033 1·02 1·86
[0·93–3·71]
0·080
White blood cells 1·01 [1·00–1·02] 0·020 1·01
[1.00–1·02]
0·148 1·01 1·01
[1·00–1·01]
0·167
Pathogen
Phylogenetic group B2 1·50 [1·06–2·12] 0·022 1·69
[1·18–2·42]
0·004* 1·06
ST131-sublineage H30Rx 1·89 [1·25–2·86] 0·003 2·09
[1·37–3·20]
b0·001*
MDR 1·62 [1·13–2·31] 0·008
Group 1 CTX-M ESBL 1·87 [1·29–2·71] b0·001 2·05
[1·40–3·01]
b0·001* 1·02
fyuA for siderophore 1·65 [1·18–2·32] 0·004 1·53
[1·08–2·16]
0·020 1·02 1·61
[1·14–2·27]
0·007*
afa for invasion 1·99 [1·15–3·45] 0·015 2·21
[1·27–3·86]
0·005* 1·01 2·11
[1·19–3·73]
0·010 1·01 2·08
[1·17–3·67]
0·012
sfa/foc for adhesion 1·65 [0·98–2·77] 0·060 1·65
[0·95–2·87]
0·074 1·03
Treatment
Delayed deﬁnitive therapy 1·54 [0·96–2·48] 0·073
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therapy = 26:2), penicillins/beta-lactamase inhibitor (10·6%,
monotherapy:combination therapy = 14:5), and ﬂuoroquinolones
(9·0%, monotherapy:combination therapy= 8:9).
3.4. Risk factors for early mortality in patients with E. coli BSI
3.4.1. Factors associated with early mortality in patients with E. coli BSI
Overall early mortality was observed in 9·5% (141/1492) cases.
Comparison of the demographic data from all survival and early death
patients are summarized in Table 1. Age distribution was similar be-
tween survival and early death groups, while patients with early
death than those of survival were more likely to be male (51·1% vs.
38·5%, P = 0.005). A greater percentage of patients with early death
were associated with HO infection (36·9% vs. 17·8%, P b 0.001), hospi-
talization (69·5% vs. 57·2%, P = 0.005) and ICU hospitalization
(31·9% vs. 8·6%, P b 0.001). Patients with early death were more likely
to have moderate or severe kidney diseases (9·9% vs. 5·5%, P =
0.039), chronic liver diseases including cirrhosis (6·4% vs. 3·0%, P =
0·043), and primary infection of peritoneum (3·5% vs. 0·5%, P =
0.003), while those were less likely than survivals to be associated
with primary UTI (31·2% vs. 46·4%, P= 0.001).
Comparison of the microbiological data for causative E. coli blood
isolates from patient groups of survival and early death are in Table 2.
A higher percentage of patients with early death were with MDR
E. coli (68·8% vs. 56·8%, P = 0.007) and CTX-M ESBL-producing E. coli
(42·6%, vs. 29·8%, P = 0.003), especially group 1 CTX-M producers
(27·0% vs. 16·0%, P = 0.002). A greater percentage of patients with
early death were with E. coli harboring the fyuA gene for yersiniabactin
(39·0% vs. 27·1%, P= 0.004), the afa gene for invasion protein (9·9% vs.
4·9%, P=0·017), and the usp gene for uropathogenic protein (56·7%
vs. 44·5%, P = 0.006). Although patients with early death were morelikely to have E. coli carrying the vat gene for vacuolating
autotransporter (26·2% vs. 19·3%) and the sfa/foc gene for S ﬁmbriae
(11·3% vs. 6·8%), the difference did not reach statistical signiﬁcance
(P= 0.059 for both).
Adequacy of empirical antimicrobial treatment had no critical im-
pact on early mortality (Table 3): 9·5% (108/1142) patients treated
with adequate empirical therapy and 10·0% (33/331) patients treated
with inadequate antimicrobials expired within 30 days. Deﬁnitive ther-
apywithin 72 hwas rather critical to earlymortality: 9·2% (13/188) pa-
tients taking punctual deﬁnitive therapy and 14·2% (20/143) patients
treated by delayed deﬁnitive therapy expired within 30 days. Even so,
adequacy of empirical antimicrobial treatment and punctuality of deﬁn-
itive treatment were neither the risk nor the protective factors for early
mortality through the analysis using Cox regressionmodel and only the
delayed deﬁnitive treatment had the risk tendency of 1·54 [1·96–2·48]
with P=0·073 (Appendix Fig. S2, Table 4).
3.4.2. Host-pathogen-treatment tripartite risk factors for early mortality by
six multivariate analysis models
In accordance with statistical speciﬁcation, clinical importance, and
multicollinearity between variables, six multivariate models were con-
structed (Table 4). The model 1 constructed by a stepwise selection
method perceived host- and pathogen-associated risk factors,
i.e., critically ill (5·85 [4·06–8·42]), primary infection of peritoneum
(2·80 [1·10–7·15]) and chronic liver diseases including cirrhosis
(2·09 [1·06–4·12]) for patient factors; and group 1 CTX-M ESBL
(2·05 [1·40–3·01]), fyuA (1·53 [1·08–2·16]) and afa (2·21
[1·27–3·86]) for pathogen factors. Primary infection of urinary tract
(0·56 [0·39–0·81]) was the one protective factor associated with pa-
tients. The multivariate models 2 to 6 constructed through clinical im-
portance, and multicollinearity discerned risk factors associated with
the tripartite component: critically ill, primary infection of peritoneum,
Multivariate
model 3
Multivariate model 4 Multivariate model 5 Multivariate model 6
VIF HR [95% CI] P VIF HR [95% CI] P VIF HR [95% CI] P VIF
Host
1·02 5·55 [3·82–8·05] b0·001* 1·02 5·72 [3·94–8·29] b0·001* 1·02 5·99 [4·13–8·68] b0·001* 1·02
1·01 1·49 [0·83–2·68] 0·185 1·01 1·53 [0·84–2·77] 0·164 1·01 1·53 [0·85–2·76] 0·159 1·01
1·01 2·88 [1·12–7·42] 0·028 1·01 3·21 [1·27–8·11] 0·013 1·01 3·02 [1·20–7·63] 0·019 1·01
1·04 0·59 [0·41–0·85] 0·005* 1·03 0·56 [0·39–0·81] 0·002* 1·03 0·61 [0·42–0·87] 0·007* 1·03
1·03 1·19 [0·66–2·15] 0·553 1·02 1·10 [0·61–1·98] 0·746 1·03 1·08 [0·59–1·96] 0·802 1·03
1·02 1·97 [0·99–3·94] 0·055 1·02 1·97 [0·99–3·94] 0·053 1·02 1·84 [0·91–3·73] 0·089 1·02
1·02 1·01 [1·00–1·02] 0·072 1·01 1·00 [1·00–1·01] 0·328 1·02 1·01 [1·00–1·01] 0·157 1·02
Pathogen
1·02
1·59 [1·10–2·29] 0·014 1·02
1·94 [1·33–2·84] b0·001* 1·02
1·01 1·60 [1·14–2·26] 0·007* 1·01 1·59 [1·13–2·25] 0·008* 1·01
1·01 2·03 [1·14–3·60] 0·016 1·01 2·03 [1·14–3·60] 0·015 1·01
1·63 [0·95–2·79] 0·075 1·01
Treatment
1·58 [0·97–2·55] 0·063 1·00
HR, hazard ratio; CI, conﬁdence interval; VIF, variance inﬂation factor; ESBL, extended-spectrum beta-lactamase; ST, sequence type.
a Multivariate analysis model 1 was constructed by a stepwise selection procedure and the other ﬁve frommodel two tomodel six were taken including ﬁxed host factors, and ﬂexible
pathogen and treatment variables: phylogenetic group B2 and afa in model 2; ST131 sublineage H30Rx, fyuA and afa in model 3; MDR, and afa/foc in model 4, group 1 CTX-M ESBL pro-
duction, fyuA and afa in model 5, and pathogen variables fyuA, and afa and a treatment variable. Bonferroni corrected signiﬁcance level was considered as P b 0.008 and the signiﬁcant P
values are indicated with asterisks.
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phylogenetic group B2, ST131-sublineage H30Rx, MDR, group 1 CTX-
M ESBL, fyuA and afa among pathogen variables. A pathogen variable
sfa/foc and a treatment variable delayed deﬁnitive therapy displayed a
risk tendency.
4. Discussions
This prospective observational study for E. coli BSI cases was under-
taken to evaluate the risk factors through an organic alliance of host-
pathogen-treatment tripartite components. Many variables were difﬁ-
cult to place in an analysis panel for a single multivariate model since
multicollinearity between variables could underestimate the risks of
each variable. Through ﬁne estimation of the multicollinearity, six mul-
tivariate models were constructed by taking into account the statistical
speciﬁcation, clinical importance, as well as intra- and inter-component
multicollinearities. Those delicate statistical models for multivariate
analysis allowed us to examine the risk factors in accordance to the
host-pathogen-treatment tripartite components. However, themultiple
comparisons could result in false discoveries in the statistical models
and multiple corrections were needed through a conservative correc-
tion test. The Bonferroni correction test, which set the signiﬁcance
cut-off at P b 0.008, disclosed critically ill and primary infection of uri-
nary tract for host-associated risk and protective factors, respectively;
phylogenetic group B2, group 1 CTX-M ESBL, fyuA, and afa for
pathogen-associated risk factors; and none for the treatment-
associated factor (Table 4).
Prior reports constantly denoted that E. coli ST131 is a worrisome
clone having an outstanding risk for extra-intestinal infections includ-
ing BSI. However, those have mostly been limited to a single-centre
study [2], a restricted origin of infection [27], collection of incidence oc-
curring in a very limited period [28], and incomplete strain typing for
E. coli isolates [28], and consequently, the results were debatable. This
one-yearmulti-centre prospective study conducting balanced complete
research allowed to highlight the ST131-sublineage H30Rx for more as-
sociationwithHO infection, primaryUTI, and earlymortality, alongwith
its renownedMDR (Fig. 2). Higher early mortality marked in the H30Rx
clone (15·6%)was in conﬂictwith the higher proportion of primaryUTI,
a protective factor against early mortality. The peculiar proportion ofrisk factors, i.e., MDR (98·3%), and group 1 CTX-M production (92·2%)
inH30Rx clone could explain the high earlymortality rate. Thehighpro-
portion of H30Rx (49·9% ST131) in this study should be noted. Getting
greater identiﬁcation of ST131-sublineage H30Rx causative for BSI is a
global issue including Canada [29], and Turkey [30]. By reason of its
weighty risk for early mortality, the dissemination of the clone needs
to be extensively scrutinized.
The ﬁrst and second dominant ST131 and ST95 clones, both in part
of the phylogenetic group B2, presented interesting contrasts. The
ST131 was mostly MDR (93·3%), frequently produced groups 1 and
9 CTX-M ESBLs (80·2%), associated with HO infections (29·2%), and
highly linked with secondary BSI from UTI (55·7%). Distinctly from
the ST131 clone, the ST95 was mostly DS (53·6%), rarely produced
beta-lactamases with extended-spectrum hydrolytic activities, associ-
ated infrequently with HO infection (11·4%), and even more linked
with primary UTI (73·6%). The most curious trait of both clones was
the resulting early mortality, 13·6% in ST131, and 5·7% in ST95
which could be led by notable differences in drug resistance, and
beta-lactamase production.
As often reported not only for the E. coli BSI but also for the BSIs by
other bacterial pathogens [15,31], the prompt deﬁnitive antimicrobial
therapy ameliorated the prognosis of BSI and the combination antimi-
crobial therapy improved adequacy of antimicrobial treatment. Both
calls attention to the antimicrobial stewardship for BSI treatment. It
was impractical to point out the choice of speciﬁc antimicrobials associ-
ated with early mortality, because the antimicrobial choice was fre-
quently dependent on the patients by their conditions. For instance,
carbapenems, of which resistance was found in only three isolates,
were adequate choices for all cases. However, a high rate of early mor-
tality was noted at 17·0% (35/206) in patients taking carbapenems
whichmust be associatedwith itsmore usage for critically ill and ICU in-
patients (Table 3). Lack of signiﬁcance in correlation between adequate
antimicrobial treatment and early mortality could be derived from the
habitual choice of antimicrobial regimen depending on the patient's
condition.
This delicate prognosis assessment for patients with E. coli BSI ac-
counting the host-pathogen-treatment tripartite component highlight-
ed the importance of i) enough review of clinical information, ii) timely
deﬁnitive therapy in accordance with the AST results, iii) strain typing
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be more informative for the E. coli BSI, an enriched panel of routine ex-
amination in clinical microbiology laboratories including strain typing
and virulence typing for pathogens should be considered. For instance,
the results from MLST and virulence typing come out with that of AST
will allow more feasible antimicrobial regimen for deﬁnitive therapy.
For sure, the current study itself cannot provide a clear guide to improve
the prognosis of E. coli BSI however, it provided a fundamental idea to
develop a prospective surveillance and concurrent intervention for the
antimicrobial stewardship plans. Moreover, a national guidance for
the management of E. coli BSI would be available out of overall efforts.
This study has several limitations. Primarily, limited races were in-
cluded. The South Korean population is composedwith relatively homo-
geneous East Asians. We did not even collect the human race data
because all but few would be East Asians. Thus, the analyzed data could
be restricted by human race. Secondly, only six out of 10 districts in
South Korea were covered. Considering population difference by district,
over 70% of South Korean populationwas able to be dealtwith. However,
the remaining 30% population was out of consideration and one of the
four districts has an absolute climate difference. Thirdly, the participating
hospitals had limited numbers of hospital beds. Numbers and ratio of in-
andoutpatients are varied by thenumber of hospital beds, and the partic-
ipating hospitals had 500 to 1000 beds. Finally, the study was conducted
for one year, which is too short to show sufﬁcient dynamics of the BSI.
In a basis of the results, a scoring system for estimating the prognosis
of E. coli BSI could be further schemed out. The SOFA scoring system is
practical and trustful to predict the outcomes of patients. However,
the system only manipulates host-associated factors. Further assessing
the BSI cases caused by other bacterial species could impart systematic
knowledge for bacterial BSI.Funding sources
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